Nascent Biotech to begin Phase 1 Human Trials for Brain Cancer Drug

SAN DIEGO, May 27, 2020 (GLOBE NEWSWIRE) -- Nascent Biotech, Inc (OTCQB: NBIO) (the Company or Nascent) is pleased to announce that the Company will soon begin Phase 1 clinical trials for a treatment of Brain Cancer, including, glioblastoma (GBM), the deadliest form of brain cancer.